TSL.L Regulatory News (TSL)

16 Apr 2007 07:01

Tissue Science Laboratories PLC16 April 2007 16 April 2007 TSL R&D Teach-in For Analysts and Investors Tissue Science Laboratories plc ('TSL' or the 'Company') (LSE: TSL), the medicaltechnology company specialising in biologic tissue replacement and repairproducts, is holding a teach-in for analysts and investors today at 9:30am atthe London Stock Exchange. In addition to representatives from the Company making presentations, two guestspeakers will be attending and speaking at the meeting - Dr Raymond Dunn, Chiefof the Division of Plastic and Reconstructive Surgery, University ofMassachusetts Medical School, and Dr Paul Sibbons of the Northwick ParkInstitute of Medical Research. Dr Dunn will be speaking about the US biologicsmarket and how he sees this market gaining traction, as well as the benefits ofTSL's porcine collagen material, Permacol(R), from the surgeon's point of view.Dr Sibbons will be speaking on current vascular graft products, why there is aneed for new products, and how TSL's developments in this field could providenew options for surgeons. Other topics covered throughout the morning will include an update on thegeneral surgery market, including TSL's progress in direct sales, marketpenetration, distribution arrangements, reimbursements and the Company's USmarket strategy. An overview of other projects will be provided, with atechnical update on the Permacol(R) material. There will also be an R&D overviewon the bone, ligament and vascular projects, including the market potential forthe individual products, the Company's progress in the development of theseprojects, and a review of the proof of principal data achieved to date. The teach-in will take place at the London Stock Exchange, 10 Paternoster Square, London, EC4M 7LS and will commence at 9:30am. For those unable to attend,presentation slides will be available on request by contacting the HogarthPartnership on tel: 020 7357 9477. -Ends- Enquiries: TSL plc Tel: +44 (0) 1252 333 002Martin Hunt, Chief ExecutiveDavid Jennings, Finance Director Hogarth PR Tel: +44 (0) 20 7357 9477Melanie Toyne-Sewell/Sarah Richardson Background on TSL Tissue Science Laboratories plc ("TSL") is a medical technology companyspecialising in tissue repair and replacement. Headquartered in Aldershot,Hampshire, TSL floated in November 2001 and is listed on AIM (AIM: TSL). TSL has a proprietary sheet product, derived from porcine dermis, calledPermacol(R). The Permacol(R) sheet product has been developed with a range ofunique properties to make it suitable for use in different applications,including urology/gynaecology, complex and recurrent hernia repair, shoulderrotator cuff repair and head and face repair and reconstruction. TSL sellsPermacol(R) directly in the complex and recurrent hernia surgical field and hassigned distribution agreements with CR Bard Inc (urology/gynaecology -worldwide) and Zimmer Inc (orthopaedic - worldwide). Different formulations of Permacol(R) have also been developed successfully,including an injectable version, based on the same core technology. In addition,TSL has built a development pipeline derived from other porcine tissues e.g.bone, ligament and vascular that addresses the large and fast growing surgicalimplant market. This information is provided by RNS The company news service from the London Stock Exchange